Abacavir - Cellceutix

Drug Profile

Abacavir - Cellceutix

Alternative Names: abacavir acetate - Cellceutix; KM-133; Prurisol

Latest Information Update: 03 Nov 2016

Price : $50

At a glance

  • Originator Unknown
  • Developer Cellceutix
  • Class Antipsoriatics; Antiretrovirals; Cyclopentanes; Cyclopropanes; Dideoxynucleosides; Small molecules
  • Mechanism of Action Immunostimulants; PRINS expression inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Psoriasis

Highest Development Phases

  • Phase II Plaque psoriasis

Most Recent Events

  • 31 Oct 2016 Cellceutix Corporation initiates enrolment in a phase IIb trial for Plaque psoriasis in USA (NCT02494479)
  • 07 Jul 2016 Cellceutix plans a phase IIb trial for Plaque psoriasis in USA in the third quarter or early in the fourth quarter 2017
  • 31 May 2016 Pharmacokinetics and adverse events data from a phase II trial in Plaque psoriasis released by Cellceutix
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top